Investors

investor-photo2

Enanta Pharmaceuticals is a clinical stage biotechnology company that uses its robust chemistry-driven approach and drug discovery capabilities to create small molecule drugs for viral infections and immunological diseases. Enanta’s clinical programs are currently focused on respiratory syncytial virus (RSV) and its earlier-stage immunology pipeline aims to develop treatments for inflammatory diseases by targeting key drivers of the type 2 immune response, with KIT, STAT6 and MRGPRX2 inhibition.

Learn More »

Volume:

Minimum 15 minutes delayed. Source: LSEG

Recent Press Releases

March 30, 2026
Enanta Pharmaceuticals to Present Data for its STAT6 Inhibitor Program at IMMUNOLOGY2026™, the Annual Meeting of the American Association of Immunologists (AAI)
March 3, 2026
Enanta Pharmaceuticals to Present at The Citizens Life Sciences Conference

Upcoming Events

More events are coming soon.